Myelodysplastic Syndromes
Showing NaN - NaN of 57
MDS Trial in Worldwide (Tamibarotene + Azacitidine, Tamibarotene Matched Placebo + Azacitidine)
Recruiting
- Myelodysplastic Syndromes
- Tamibarotene + Azacitidine
- Tamibarotene Matched Placebo + Azacitidine
-
Tucson, Arizona
- +87 more
Feb 2, 2023
MDS Trial in Worldwide (Magrolimab, Azacitidine, Placebo)
Active, not recruiting
- Myelodysplastic Syndromes
- Magrolimab
- +2 more
-
Birmingham, Alabama
- +168 more
Dec 7, 2022
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, MDS Trial in Canada, United States (ASTX727)
Enrolling by invitation
- Acute Myeloid Leukemia
- +2 more
-
Fountain Valley, California
- +28 more
Nov 18, 2022
MDS, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute Trial in Worldwide (Azacitidine, Pevonedistat)
Completed
- Myelodysplastic Syndromes
- +2 more
-
Birmingham, Alabama
- +58 more
Aug 24, 2022
Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies Trial
Recruiting
- Relapsed or Refractory Acute Myeloid Leukemia (AML)
- +3 more
-
Birmingham, Alabama
- +26 more
Sep 12, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia Trial in United States (drug,
Recruiting
- Acute Lymphoblastic Leukemia
- +7 more
- Busulfan
- +11 more
-
Duarte, California
- +26 more
Aug 11, 2022
MDS Trial in Worldwide (Luspatercept, Placebo)
MDS, Leukemia, Myelomonocytic, Chronic Trial in Worldwide (Guadecitabine, Treatment Choice)
Completed
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- Guadecitabine
- Treatment Choice
-
Duarte, California
- +95 more
Sep 1, 2021
MDS Trial in France, Germany, United States (Oral rigosertib)
Completed
- Myelodysplastic Syndromes
- Oral rigosertib
-
Stanford, California
- +13 more
Jun 15, 2021
Connect® Myeloid Disease Registry
Recruiting
- Primary Myelofibrosis
- +2 more
-
Huntsville, Alabama
- +228 more
Mar 30, 2021
MDS Trial in Canada, United States (anti-thymocyte globulin)
Completed
- Myelodysplastic Syndromes
- anti-thymocyte globulin
-
Washington, District of Columbia
- +27 more
Jan 24, 2021
MDS, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia Trial in Worldwide (rigosertib sodium)
Completed
- Myelodysplastic Syndromes
- +3 more
- rigosertib sodium
-
Stanford, California
- +34 more
Jun 29, 2020
MDS, MDS, RAEB Trial in Worldwide (ON 01910.Na)
Completed
- Myelodysplastic Syndromes
- +3 more
- ON 01910.Na
-
Scottsdale, Arizona
- +86 more
Jun 29, 2020
MDS Trial in Germany, United States (lenalidomide)
Completed
- Myelodysplastic Syndromes
-
Scottsdale, Arizona
- +31 more
Nov 6, 2019
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Tumor Trial in Baltimore (biological, drug, procedure)
Completed
- Leukemia
- +3 more
- daclizumab
- +4 more
-
Baltimore, MarylandMarlene & Stewart Greenebaum Cancer Center, University of Maryla
Oct 31, 2019
Anemia, GVHD, Leukemia Trial in Baltimore (biological, drug, procedure, radiation)
Completed
- Anemia
- +5 more
- anti-thymocyte globulin
- +6 more
-
Baltimore, MarylandMarlene & Stewart Greenebaum Cancer Center, University of Maryla
Oct 15, 2019
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Tumor Trial in Baltimore (biological, drug, procedure, radiation)
Completed
- Leukemia
- +3 more
- anti-thymocyte globulin
- +5 more
-
Baltimore, MarylandMarlene & Stewart Greenebaum Cancer Center, University of Maryla
Oct 15, 2019
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Tumor Trial in Baltimore (filgrastim, therapeutic allogeneic lymphocytes,
Completed
- Leukemia
- +3 more
- filgrastim
- +3 more
-
Baltimore, MarylandMarlene & Stewart Greenebaum Cancer Center, University of Maryla
Oct 15, 2019
Leukemia, MDS Trial in Atlanta, Baltimore (bevacizumab, cytarabine, mitoxantrone HCl)
Completed
- Leukemia
- Myelodysplastic Syndromes
- bevacizumab
- +2 more
-
Atlanta, Georgia
- +2 more
Oct 15, 2019
MDS Trial in Baltimore (K562/GM-CSF cell vaccine)
Terminated
- Myelodysplastic Syndromes
- K562/GM-CSF cell vaccine
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oct 18, 2018
Leukemia, MDS, Myelodysplastic/Myeloproliferative Diseases Trial in Baltimore (biological, drug, genetic, other, procedure)
Completed
- Leukemia
- +2 more
- sargramostim
- +6 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sep 7, 2018